ReviewMaterials today. Bio2025
Bioactive LDH nanoplatforms for cancer therapy: Advances in modulating programmed cell death.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of STAT3 in regulating ferroptosis in cancer: molecular mechanisms and targeted therapeutic perspectives.Cancer gene therapy · 2026Review
- Biodegradable Mn-LDH-Ce6 potentiates cGas-STING pathway activation through sonodynamic-propelled pyroptosis for synergistic tumor immunotherapy.Ultrasonics sonochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the rapid advancement of nanotechnology and tumor biology has significantly expanded the application of nanomaterials in cancer therapy, particularly through the induction of programmed cell death (PCD) in cancer cells. Layered double hydroxides (LDH), a class of two-dimensional inorganic nanomaterials, have attracted considerable attention due to its tunable structures, excellent biocompatibility, and superior drug delivery capabilities. Emerging research has highlighted the great potential of LDH in modulating various forms of PCD. In this review, we provide a comprehensive overview of recent progress in the use of LDH to regulate different PCD pathways in cancer cells, including apoptosis, autophagy, ferroptosis, cuproptosis and pyroptosis. It emphasizes the underlying mechanisms of action, material design strategies, and the application of LDH in precise cancer therapy. Finally, this review is concluded with perspectives on the key challenges and bottlenecks of bioactive LDH in cancer therapy, providing potential solutions and outlining future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.